Lidocaine and Benzocaine Sprays Show Equal Efficacy in Reducing IV Catheter Pain

What’s New in Pre-IV Catheter Pain Management?

Turkish researchers have demonstrated that both lidocaine 10% and benzocaine 20% sprays significantly reduce pain during peripheral intravenous catheterization compared to placebo, according to results from a Phase III randomized controlled trial. The study, conducted at a university hospital emergency department, showed comparable efficacy between the two anesthetics, with both significantly improving patient satisfaction scores.

The trial, registered as NCT04859738, evaluated 120 participants divided equally into three groups receiving either lidocaine spray, benzocaine spray, or placebo prior to peripheral IV catheter insertion. Researchers found that pain scores measured on the Visual Analog Scale (VAS) were dramatically lower in both treatment groups compared to the placebo group (7.72±7.76 for lidocaine, 6.82±5.75 for benzocaine, versus 32.65±17.20 for placebo; p<0.001). Patient satisfaction was correspondingly higher in both treatment groups (95.47±4.31 for lidocaine, 95.90±3.88 for benzocaine, versus 75.37±13.45 for placebo; p<0.001). Notably, no statistically significant differences were observed between the lidocaine and benzocaine groups, suggesting both are equally effective for this application. The researchers also identified a strong negative correlation between pain scores and satisfaction levels across all groups, reinforcing the importance of pain management during catheterization procedures.

Why Is Effective Pain Management During IV Catheter Insertion Vital?

Peripheral IV catheterization is one of the most common invasive procedures performed in healthcare settings, with estimates suggesting over one billion PIVCs are used annually worldwide. The pain associated with catheter insertion can lead to increased anxiety, vasospasm, and potentially multiple insertion attempts, making effective pain management strategies crucial for both patient comfort and procedural success. While previous research had established lidocaine's effectiveness for this purpose, this study represents one of the first rigorous evaluations of benzocaine spray for peripheral IV catheterization pain management. The researchers noted that the application of topical anesthetics was simple, quick, and caused no adverse events during the trial, suggesting a favorable risk-benefit profile.

The investigators employed a double-blind methodology, with both patients and researchers unaware of group assignments. To ensure standardization, the same nurse performed all catheterizations using identical 20-gauge catheters inserted at the median cubital vein. Pain thresholds were carefully assessed using a dolorimeter to ensure comparable baseline sensitivity among participants. The topical anesthetics were applied 60 seconds before catheterization, allowing sufficient time for the onset of local anesthetic effects.

What Makes These Anesthetics Work?

The study authors explained that lidocaine and benzocaine, though both local anesthetics, work through different chemical mechanisms. Lidocaine is categorized as an amide local anesthetic, while benzocaine belongs to the ester class. Both agents decrease nerve cell membrane permeability to sodium, effectively blocking nerve impulses and causing temporary loss of sensation at the application site. The onset of anesthetic effects typically ranges from 1-5 minutes, with absorption rates and duration dependent on factors including dose, concentration, application site, and application duration.

These findings could influence clinical practice by offering healthcare providers multiple options for pre-procedural analgesia during IV catheterization. The comparable efficacy of benzocaine to the more widely studied lidocaine provides clinicians with an alternative that may be particularly valuable in cases of patient allergies or institutional formulary restrictions. While both agents function as local anesthetics, their different chemical classifications affect their pharmacokinetic profiles and potential adverse effect patterns.

The researchers acknowledged several limitations, including the subjective nature of pain assessment and the study's focus on adult patients only, cautioning against generalizing results to pediatric populations. They recommended further research with larger and more diverse patient populations to validate their findings.

How Does This Research Impact the Broader Healthcare Landscape?

Industry Context: This study aligns with increasing emphasis on patient-centered care and procedural comfort in healthcare settings. As health systems worldwide focus on improving patient experience metrics and reducing procedural complications, interest in simple, cost-effective interventions like topical anesthetics continues to grow. The pharmaceutical industry has seen renewed interest in reformulations and novel delivery systems for established anesthetics, with several companies developing specialized products for procedural pain management in both hospital and outpatient settings.

Summary

A Phase III randomized controlled trial conducted in Turkey has demonstrated that both lidocaine 10% spray and benzocaine 20% spray significantly reduce pain during peripheral intravenous catheterization compared to placebo. The study, involving 120 participants divided into three groups, found that pain scores on the Visual Analog Scale were dramatically lower for both anesthetic treatments (7.72 for lidocaine and 6.82 for benzocaine versus 32.65 for placebo), while patient satisfaction scores were correspondingly higher (95.47 for lidocaine and 95.90 for benzocaine versus 75.37 for placebo). Notably, no significant differences were observed between the lidocaine and benzocaine groups, indicating comparable efficacy. Both anesthetics work by blocking nerve impulses through decreased sodium permeability in nerve cell membranes, though they belong to different chemical classes—lidocaine is an amide and benzocaine is an ester. The findings are particularly relevant given that over one billion peripheral IV catheters are used annually worldwide, and effective pain management can reduce anxiety, prevent vasospasm, and decrease the need for multiple insertion attempts. The study's results provide clinicians with validated alternatives for pre-procedural analgesia, especially valuable in cases of patient allergies or formulary restrictions, while supporting the broader healthcare emphasis on patient-centered care and improved procedural comfort.